Annual Accounts Receivable
$48.49 M
+$14.77 M+43.78%
December 31, 2023
Summary
- As of February 7, 2025, ESPR annual accounts receivable is $48.49 million, with the most recent change of +$14.77 million (+43.78%) on December 31, 2023.
- During the last 3 years, ESPR annual accounts receivable has risen by +$36.11 million (+291.46%).
- ESPR annual accounts receivable is now at all-time high.
Performance
ESPR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$67.82 M
+$7.46 M+12.37%
September 30, 2024
Summary
- As of February 7, 2025, ESPR quarterly accounts receivable is $67.82 million, with the most recent change of +$7.46 million (+12.37%) on September 30, 2024.
- Over the past year, ESPR quarterly accounts receivable has increased by +$7.46 million (+12.37%).
- ESPR quarterly accounts receivable is now at all-time high.
Performance
ESPR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ESPR Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +43.8% | +12.4% |
| 3 y3 years | +291.5% | +12.4% |
| 5 y5 years | - | - |
ESPR Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +111.5% | at high | +195.7% |
| 5 y | 5-year | at high | +291.5% | at high | +447.5% |
| alltime | all time | at high | +291.5% | at high | +447.5% |
Esperion Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $67.82 M(+12.4%) |
| Jun 2024 | - | $60.36 M(+10.5%) |
| Mar 2024 | - | $54.61 M(+12.6%) |
| Dec 2023 | $48.49 M(+43.8%) | $48.49 M(+13.8%) |
| Sep 2023 | - | $42.62 M(+4.5%) |
| Jun 2023 | - | $40.80 M(+12.0%) |
| Mar 2023 | - | $36.41 M(+8.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $33.73 M(+47.1%) | $33.73 M(+7.1%) |
| Sep 2022 | - | $31.49 M(+13.1%) |
| Jun 2022 | - | $27.84 M(+10.9%) |
| Mar 2022 | - | $25.12 M(+9.5%) |
| Dec 2021 | $22.93 M(+85.1%) | $22.93 M(+5.6%) |
| Sep 2021 | - | $21.71 M(-0.7%) |
| Jun 2021 | - | $21.85 M(+76.4%) |
| Dec 2020 | $12.39 M | $12.39 M |
FAQ
- What is Esperion Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Esperion Therapeutics?
- What is Esperion Therapeutics annual accounts receivable year-on-year change?
- What is Esperion Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly accounts receivable year-on-year change?
What is Esperion Therapeutics annual accounts receivable?
The current annual accounts receivable of ESPR is $48.49 M
What is the all time high annual accounts receivable for Esperion Therapeutics?
Esperion Therapeutics all-time high annual accounts receivable is $48.49 M
What is Esperion Therapeutics annual accounts receivable year-on-year change?
Over the past year, ESPR annual accounts receivable has changed by +$14.77 M (+43.78%)
What is Esperion Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of ESPR is $67.82 M
What is the all time high quarterly accounts receivable for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly accounts receivable is $67.82 M
What is Esperion Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, ESPR quarterly accounts receivable has changed by +$7.46 M (+12.37%)